



DATE: JULY 18, 2019

SUBJECT: ARATANA THERAPEUTICS, INC. – CONTRACT ADJUSTMENT
OPTION SYMBOL: 7/18/19 – PETX remains PETX
7/19/19 – PETX becomes ELAN1
DATE: 07/18/19

CONTRACT ADJUSTMENT

DATE: July 18, 2019

OPTION SYMBOL: 7/18/19 – PETX remains PETX (with adjusted deliverable described below)
7/19/19 – PETX changes to ELAN1

STRIKE DIVISOR: 1

**CONTRACTS
MULTIPLIER:** 1

NEW MULTIPLIER: 100 (e.g., a premium of 1.50 yields \$150; a strike of 5 yields \$500.00)

**NEW DELIVERABLE
PER CONTRACT:** 1) 14 Elanco Animal Health Incorporated (ELAN) Common Shares
2) Cash in lieu of 0.81 fractional ELAN shares

Note: The PETX option deliverable will not be adjusted to include non-transferrable Contingent Value Rights.

CUSIP: ELAN: 28414H103

PRICING

Until the cash in lieu of fractional shares is determined, the underlying price for ELAN1 will be determined as follows:

$$\text{ELAN1} = 0.1481 \text{ (ELAN)}$$

DELAYED SETTLEMENT

The ELAN component of the ELAN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the ELAN1 deliverable until the cash

in lieu of fractional ELAN shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

BACKGROUND

On July 16, 2019, Shareholders of Aratana Therapeutics, Inc. (PETX) voted concerning the proposed merger with Elanco Animal Health Incorporated (ELAN). The merger was approved and subsequently consummated before the open on July 18, 2019. As a result, each existing PETX Common Share will be converted into the right to receive 0.1481 ELAN Common Shares and one non-transferrable Contingent Value Right ("CVR"). Cash will be paid in lieu of fractional ELAN shares.

NOTE: The Contingent Value Rights represent a non-transferrable contractual right to receive an additional payment. The adjusted ELAN1 option deliverable will not include the non-transferrable CVRs.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.